Appln. No. 10/666,335 Amd. dated February 19, 2008 Reply to Office Action of September 19, 2007

Amendments to the Claims

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

Claims 1-19 (Cancelled).

20 (Currently amended). A pharmaceutical composition for treating endometriosis-related infertility, comprising an anti-TNF antibody or a fragment thereof, a pharmaceutically acceptable carrier, and a biologically active hormone selected from the group consisting of biologically active human chorionic gonadotropin (hCG), biologically active luteinising hormone (LH), and biologically active follicle stimulating hormone (FSH).

 $21 \, (\text{Previously presented})$. The pharmaceutical composition of claim 20, wherein said biologically active hormone is hCG.

22 (Previously presented). The pharmaceutical composition of claim 20, wherein said biologically active hormone is LH.

23(Previously presented). The pharmaceutical composition of claim 20, wherein said biologically active hormone is FSH.

Appln. No. 10/666,335 Amd. dated February 19, 2008 Reply to Office Action of September 19, 2007

24(Previously presented). The pharmaceutical composition of claim 20, wherein said anti-TNF antibody or fragment thereof is selected from the group consisting of a chimeric monoclonal antibody, a humanized monoclonal antibody, and fragments thereof.